DIRS.INFO The most relevant business & tech news

☆ Here are the six trades and the two price-target changes the Club made this week
▼ + stars: | 2023-08-11 | by ( Morgan Chittum | ) www.cnbc.com time to read: +7 min

During another busy week of earnings and stock market swings, we picked our spots and made six trades, including calling up a Bullpen name. We also changed two Club price targets. Shortly after the opening bell, we trimmed some Caterpillar and booked some profits after the industrial giant's blowout earnings last week. Jim Cramer's Charitable Trust — the holdings we use for the Club — owns 315 shares of Caterpillar. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer's, Club —, Stanley Black, Decker, Stanley, Wolfe, Eli Lilly, Lilly, Bob Iger's, Jeff Marks, Jim Cramer, Jim, Jim Cramer Rob Kim Organizations: Caterpillar, DuPont, Revenue, Club, Management, Coterra Energy, West Texas, Wolfe Research, Halliburton, HAL, GE Healthcare Technologies, Disney, The, GE Healthcare, pharma, Big Tech, CNBC Locations: Coterra

☆ Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
▼ + stars: | 2023-08-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly also increased its adjusted earnings guidance to a range of $9.70 to $9.90 per share for the year, up from a range of $8.65 to $8.85. Shares of Eli Lilly jumped 9% in premarket trading Tuesday. Last month, Eli Lilly filed for Food and Drug Administration approval of the injection for chronic weight management. Eli Lilly said it "has experienced and continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand." Eli Lilly also reported no sales from its Covid-19 antibody treatments, compared with $129 million in the second quarter of 2022.

Persons: Eli Lilly, Here's, Alimta, Alimta's Organizations: Getty, Refinitiv, Food and Drug, Amphastar Pharmaceuticals, Drug Administration, . Pipeline Locations: U.S

☆ Here's a list of weight-loss drugs in development and awaiting approval to take on Ozempic
▼ + stars: | 2023-06-28 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +10 min

The company's chief rival, Denmark-based Novo Nordisk (NVO), also published promising data on drugs in its pipeline, including its own oral weight-loss treatment. Other pharmaceutical companies are racing to compete with Novo Nordisk and Eli Lilly, including Amgen (AMGN) and Pfizer (PFE). Barclays on Tuesday projected Eli Lilly's three leading obesity-and-diabetes drugs could generate nearly $49 billion in combined sales in 2030. Eli Lilly Eli Lilly has multiple drugs in development that fall under the GLP-1 umbrella in various stages of clinical development. Novo Nordisk Novo Nordisk currently dominates the market for GLP-1 drugs, with three products in the class on the U.S. market already: Ozempic, Wegovy and Rybelsus.

Persons: It's, Eli Lilly, Eli Lilly's, retatrutide, Lilly, there's, Lilly's, Geoff Meacham, Eli Lilly Eli Lilly, Jim Cramer, Evan David Seigerman, —, — Morgan Stanley, Wegovy, Rybelsus, Jim Cramer's, Jim, Mike Segar Organizations: Club, Novo Nordisk, New England, of Medicine, American Diabetes Association, Pfizer, Reuters, Barclays, Bank of America, CNBC, JPMorgan, Drug Administration, Equity, BMO Capital, Novo Nordisk Novo Nordisk, GLP, FDA, Nordisk, Company Locations: San Diego, Denmark, GLP, It's, Novo, Novo Nordisk's, Branchburg , New Jersey

☆ CNBC Daily Open: Rethinking the rally
▼ + stars: | 2023-06-21 | by ( Yeo Boon Ping | ) www.cnbc.com time to read: +2 min

This report is from today's CNBC Daily Open, our new, international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Rally haltedU.S. markets closed in the red Tuesday, halting a rally that drove stocks to their highest levels in more than a year. The UK 'doom loop'The U.K. economy is trapped in a growth "doom loop," according to the country's Institute for Public Policy Research. The International Monetary Fund expects the U.K. economy to grow 0.4% this year.

Persons: Germany's DAX, Eli Lilly, Thali, Narendra Modi, Joe Biden, Biden, Tim Cook, Alphabet's Sundar Pichai, Satya Nadella, Raj Subramaniam, Goldman Sachs, Goldman Organizations: New York Stock Exchange, CNBC, Dice Therapeutics, country's Institute for Public Policy Research, Monetary Fund, U.S, House Locations: New York City, San Francisco, India, China

☆ Here's our internal debate about what to do with stocks making all-time highs
▼ + stars: | 2023-06-16 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

All of the following stocks hit all-time price highs Friday, except for Meta Platforms (META), which was a multiyear high. Apple P/E next 12 months (NTM) ratio: 29x 5 year Average P/E (NTM): 22.7x PEG (NTM) ratio: 2.9x 5 year average PEG (NTM) Ratio: 1.9x Apple 's (AAPL) valuation has gotten stretched in recent weeks, even when factoring in growth expectations. Meta Platforms P/E (NTM) ratio: 21.4x 5 year Average P/E (NTM): 21.2x PEG (NTM) ratio: 1.6x 5 year average PEG (NTM) Ratio: 2.2x Meta has been on an incredible run. Microsoft P/E (NTM) ratio: 31.7x 5 year Average P/E (NTM): 27.7x PEG (NTM) ratio: 2.5x 5 year average PEG (NTM) ratio: 2.1x Microsoft's run has seen its earnings-based valuation (P/E) expand, even when adjusting for growth (PEG). NVDA YTD mountain Nvidia YTD performance Nvidia has a history of beating estimates and ending up cheaper in hindsight.

Persons: Jim Cramer, Jim, we've, Rather, Eli Lilly P, Eli Lilly's, Eli Lilly YTD, Lilly, we're, Eli Lilly, Jim Cramer's, Michael Nagle Organizations: Nasdaq, Nvidia, Meta, Apple, UBS, Credit Suisse, Mounjaro, Microsoft, Palo Alto Networks, CNBC, Bloomberg, Getty Locations: —, Palo

☆ How promising are new drugs to treat obesity?
▼ + stars: | 2023-05-05 | by ( Katia Hetter | ) edition.cnn.com time to read: +8 min

CNN —The pharmaceutical company Eli Lilly announced last week that a medication developed to treat diabetes, tirzepatide, also had a substantial effect on reducing weight. Another pharmaceutical company, Novo Nordisk, manufactures the medication semaglutide, which the FDA has already approved to treat diabetes under the brand name Ozempic and to treat obesity under the brand name Wegovy. How promising are they to treat obesity? CNN: How promising are these drugs to treat obesity? It is really important to treat obesity as the disease that it is — and having effective medications to do so is crucial.

☆ Positive Alzheimer's drug trial data pushes Eli Lilly shares to another all-time high and brightens our outlook
▼ + stars: | 2023-05-03 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

LLY 1Y mountain Shares of Eli Lilly over the past 12 months. The FDA granted accelerated approval to an anti-amyloid drug — developed by Japanese pharmaceutical firm Eisai and U.S.-based partner Biogen (BIIB) — in early January. For Eli Lilly, specifically, Seigerman said the donanemab data appears to be a "home run." Eli Lilly said two participants in the Phase 3 trial died due to ARIA side effects, while a third patient did after a serious ARIA incident. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

Patients who took Eli Lilly 's weight loss drug tirzepatide lost up to 34 pounds on average, or 16% of their body weight, the company said in clinical trial results released Thursday. Eli Lilly plans to complete its application for Food and Drug Administration approval of the drug in the coming weeks and expects regulatory action as early as later this year. The FDA approved tirzepatide for Type 2 diabetes last year, but the drug is not cleared for weight loss. The approval would open "up the opportunity for many more people to benefit from tirzepatide," Eli Lilly CEO David Ricks said Thursday on CNBC's "Squawk Box." He added that the drug sets a "new bar for weight loss and people with diabetes."

☆ Eli Lilly jumps to all-time highs on Alzheimer's news. Here's what it means our investment
▼ + stars: | 2023-04-21 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +6 min

LLY 1Y mountain Shares of Eli Lilly over the past 12 months. Still, a commercially successful Alzheimer's drug would be material for Eli Lilly and strengthen its long-term position. Mounjaro is the heart of our Eli Lilly investment case. Another catalyst looming for Eli Lilly shares is results from a study conducted by its competitor in the weight-loss category Novo Nordisk . Eli Lilly Pharmaceutical company logo SOPA Images | LightRocket | Getty Images

☆ Going Into 2023, CIOs Weigh Tech Priorities Against Economic Realities
▼ + stars: | 2022-12-23 | by ( Angus Loten | ) www.wsj.com time to read: +6 min

Bonnie Titone, chief information officer at Duke Energy Corp., a Charlotte, N.C.-based power producer, said CIOs are being told to get by with less, but without decreasing output or positive outcomes. Newsletter Sign-up WSJ | CIO Journal The Morning Download delivers daily insights and news on business technology from the CIO Journal team. One resource to keep top of mind is talent, said Brad Peterson, Nasdaq Inc.’s chief technology and chief information officer, adding that economic slowdowns can provide opportunities to reassess talent development and succession planning. Diogo Rau, chief information and digital officer at Eli Lilly Photo: Eli Lilly & Co. “My perceptions of the economy haven’t changed the way I plan to approach my role,” said Diogo Rau, chief information and digital officer at Eli Lilly & Co.

☆ Jim Cramer's Investing Club meeting Monday: Industrials, buying tech, Eli Lilly
▼ + stars: | 2022-12-19 | by ( Krystal Hur | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Still bullish on Eli Lilly The Food and Drug Administration (FDA) added Eli Lilly 's (LLY) new type-2 diabetes drug Mounjaro to its list of drugs in short supply , highlighting strong demand for the medication. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Elon Musk's Twitter account displayed on a mobile with Elon Musk in the background are seen in this illustration. Leaders of major civil rights groups are denying accusations made by Elon Musk, who said they broke an agreement with him by encouraging companies to halt advertising on Twitter . "The main person responsible for the Twitter advertiser exodus is Elon Musk. "We're basically asking Elon Musk, who we all know is a rather creative person, to take leadership in this area," Cooper said. Under Musk's leadership, Twitter rolled out and promptly rolled back a Twitter Blue Verified subscription service, after users who purchased the badges were able to impersonate celebrities, politicians and brands.

☆ Credit Suisse touts drug stocks as a top place to be. These are our 2 favorites
▼ + stars: | 2022-11-18 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Like the Club, Credit Suisse holds a positive view on Mounjaro — the company's diabetes drug that's shown immense promise as an obesity treatment, too — and Lilly's latest experimental Alzheimer's drug ahead of a pivotal data release expected next year. However, we differ on J & J, which will soon break itself up. The remaining J & J will be its current pharmaceutical and medical technologies divisions. Credit Suisse rates J & J as neutral with a $170 price target, which is nearly 4% below where the stock closed Thursday. A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

Search resuls for: "Eli Lilly P"

13 mentions found